IFN-γ treated cancer cells secreted a high amount of immune stimulatory TEVs that enhance the number of M1 macrophages by improving their capacity to ingest TEVs and promoting antibody production against cancer cells [216] as well as reducing Tregs and suppressing the expression of PD-L1, VEGF receptor 2, and IDO-1 [217]. The gene discussed is IFNG; the disease is cancer.